EDGAR 10-K Filing

Company CIK: 1746563
Filing Year: 2021
Filename: 1746563_10-K_2021_0001477932-21-006778.json

---

ITEM 1. BUSINESS
ITEM 1. BUSINESS
Our Corporate History and Background
The Company’s primary business is conducted through its subsidiary, First Capital Venture Co., whose wholly-owned subsidiary, CBD, LLC, does business under the trade style, Diamond CBD (“Diamond CBD”) and is engaged in the development and sales of hemp-derived CBD oil containing products, the majority of which contain “Full Spectrum CBD”, “Broad Spectrum CBD”, or “CBD Isolate”. For all practical purposes First Capital Venture Co. conducts its business as Diamond CBD.
Hemp-derived CBD is distinguishable from CBD derived from marijuana. Hemp-derived CBD contains not more than 0.3 percent of THC, while marijuana contains in excess of this amount. As such, we believe that our hemp-derived CBD products are regulated under the Agricultural Act of 2018, commonly known as the “Farm Bill”.
The 2018 Farm Bill allows for the interstate sale and transfer of hemp-derived products for commercial or other purposes. It also puts no restrictions on the sale, transport, or possession of hemp-derived products, so long as those items are produced in a manner consistent with the law. The Farm Bill ensures that any cannabinoid-components of CBD -that is derived from hemp will be legal, if that hemp is produced in a manner consistent with the Farm Bill, associated federal regulations, associated state regulations, and by a licensed grower as defined in the Farm Bill.
The Company maintains that all products produced and marketed by it, are in compliance with the Farm Bill and all other federal and state law and regulation. Diamond CBD offers its products for sale direct to consumers via its website at http://www.diamondcbd.com, as well as through distributors and resellers in the United States.
Corporate History
PotNetwork Holdings, Inc., (the “Company” or the “Registrant”) was originally incorporated in Nevada in 1988 as H P Capital Corp.
In 1996, it changed its name to Araldica Wineries Ltd., and in 2000, to Interactive Solutions Corp, which in 2004, reverse merged with y Medical CD, Ltd., and redomiciled to Wyoming. The Company then underwent a series of name changes: United Treatment Centers, Inc., from June 26, 2008 to February 4, 2013, Element Trading Holding Inc., from February 4, 2013-March 5, 2014, United Treatment Centers, Inc., from March 5, 2014 to July 21, 2015, PotNetwork Holdings Inc., from July 21, 2015 to May 20, 2016, SND Auto Group, Inc., from May 20, 2016 to January 5, 2017, and to PotNetwork Holdings Inc. on January 30, 2017. On March 3, 2017, the Company as PotNetwork Holdings, Inc., redomiciled to Colorado.
On January 30, 2017, the Company acquired via reverse triangular merger 100% of the ownership interest of the privately-held First Capital Venture Co., a Florida corporation. First Capital Venture Co. through CBD, LLC doing business as Diamond CBD, was selling numerous CBD and related products at both wholesale and retail, and by direct ecommerce sales to consumers over the age of 18.
Pursuant to a Share Exchange and Reorganization Agreement, the First Capital Venture Co. shareholders exchanged their shares which they held in First Capital Venture Holdings Co. for an aggregate total of 50,000 Class A preferred shares of the Company, wherein the shareholders would own 100% of this class of stock of the Company (the “Class A Preferred Shareholders”), which in the aggregate conferred voting control of the Company. First Capital Venture Co. became a wholly-owned subsidiary of the Company as result of the transaction.
In a separate transaction, on June 8, 2017, pursuant to a Stock Purchase Agreement PotNetwork Holdings Inc. acquired all the capital stock of PotNetwork Media Group, Inc., a Nevada corporation (“PMG”), in exchange for 3,000,000 shares of the Company’s common stock issued to the shareholders of PMG, and the cancellation of an outstanding $50,000 promissory note between the Company and PMG. As a result, PMG became a wholly-owned subsidiary of the Company. PMG is the owner of the website www.potnetwork.com. Potnetwork.com is an informational website on the overall cannabis industry and does not market any products.
PotNetwork Holdings Inc., therefore, has two (2) wholly-owned subsidiaries:
●
First Capital Venture Co., a Florida corporation which has as its wholly-owned subsidiary, CBD, LLC, a Florida limited liability company, doing business nationally as Diamond CBD; and
●
PotNetwork Media Group, Inc., a Nevada corporation, operator of the website, PotNetwork.com.
Existing Products
First Capital Venture Co. through its wholly-owned subsidiary, CBD, LLC, using the trade style of Diamond CBD, offers numerous products that are marketed under several brand names, including “Diamond CBD”, “Chill”, “Relax”, “MediPets” and the premium “Meds BioTech” label, as well as several others. In total, under its various brand names, Diamond CBD offers hundreds of products in variations by flavor, concentration and size that are sold direct to consumers over its website, http://www.diamondcbd.com/, and over a nationwide distribution network of distributors and resellers that sell to thousands of brick-and-mortar retailers and other online merchants.
The overall product line, because of its size, is constantly in flux as new products are added and products are culled based on several factors including, but not limited to, consumer acceptance. For example, due to consumer demand, Diamond CBD has recently added to its product line, additional CBD derivative products that it believes are subject to the same federal regulation under the Farm Bill as are its other CBD products.
While most of the products marketed under the Diamond CBD brand are geared to human health and wellness, its “MediPets” product line is a 100% natural and organic cannabinoid oil-based health and wellness solution for dogs and cats. Along with the Company’s Pet CBD food for small, medium, large dogs and cats, these products offer pet owners a new way to support their pet’s mood and wellness in a non-invasive, non-toxic way. Technavio, a leading market research firm, recently analyzed the global pet care industry and forecasted a CAGR of 5% between 2018-2022 (Global Pet Dietary Supplements Market 2018-2022, March 2018). According to that report, rising pet ownership combined with increased consumer spending on premium natural and organic pet care products are fundamental factors driving that growth.
Under Diamond CBD’s various brands, its products containing CBD and CBD derivatives may be grouped into the following categories:
·
Flavored and unflavored oils in varying concentrations
·
Vaping pens and additives
·
Edibles such as chewable “gummies”, and lollipops
·
Capsules
·
Beverage energy/relaxation “shots”
·
Topical application creams in various concentrations (including the premium “Meds BioTech” brand)
·
Dog and cat wellness products in various dosages and delivery formats (the “MediPets” brand)
·
Skin care, bath and body products
·
Hemp flowers
Product Formulation and Production
Diamond CBD uses its commercial suppliers and contract manufacturers for product research and development, formulation, quality testing, production and packaging. These suppliers and manufacturers hold, as required, the necessary regulatory and other licenses/permits specific to each’s activity. All customer order fulfillment is outsourced under a drop shipment fulfillment model. As a result, the Company does not hold any inventory but rather inventory is held by the drop shipper.
Products and formulations are routinely tested for purity and consistency of active ingredient concentration by third-party laboratories holding the necessary regulatory and other licenses/permits. The Company owns its own propriety formulas for its proprietary products, which it regards are trade secrets (the Company nor its subsidiaries do not own any patents nor have any patents pending on its proprietary products). Through its suppliers, Diamond CBD continuously is engaged in both new product development, product testing and product incremental improvement through its suppliers.
Sales Channels
In addition to selling its products directly to consumers, Diamond CBD depends upon a network of distributors and resellers to market and sell its products nationally where permitted by law. As a result, the Company’s brands are sold through an informal network of thousands of retail points of distribution. No single distributor represents more than 10% of the Company’s aggregate sales volume. The Company continuously evaluates the performance of its distributors and sales channels and periodically restructures or updates its methods of distribution.
The Markets for Our Products
It is expected that U.S. consumer sales of cannabidiol (CBD) will reach around 1.8 billion U.S. dollars by 2022, which would represent a significant increase from around half a billion U.S. dollars in 2018. Following a similar trajectory, sales of legal cannabis in the U.S. are projected to hit 23 billion U.S. dollars in 2025. (Source: https://www.statista.com/statistics/760498/total-us-cbd-sales/) The growth of the market shows that hemp-derived CBD products have become “mainstream” as consumers increasingly perceive them as providing wellness benefits.
Consumer markets served by the Company’s brands are extensive. In terms of geography, its products are sold wherever legal and the Company stipulates to its distribution channels that the products may only be sold to end-user persons eighteen years of age or older (See Item 1A “Risk Factors” for a further explanation of the laws regarding the sale of CBD products).
Initially, the Company focused distribution on market segments receptive to CBD products, such as vape shops, smoke shops and various countercultural focused retail outlets. Distribution efforts were greatly expanded from 2017 through 2020 as the result of investment in new products and channel marketing (e.g., product catalogues and sell sheets, trade show and conference attendance, channel specific sales force), resulting in a broadening of its distribution footprint and segment market penetration. For example, with the addition of specialized product lines, such as Meds BioTech and MediPets, the Company is entering into new market segments such as vitamin/supplement shops, fitness centers, and pet supply stores.
Since its inception, the strategic intent of the Diamond CBD marketing plan has been to create a defendable “marketing wall” around its distribution channels and retail outlets to minimize competitive incursions. The maintenance of such a marketing wall requires ongoing investment and vigilance. Consequently, the Company continues to expend a significant portion of its gross revenue on sales and marketing efforts to build/support consumer awareness and brand preference, as well as to drive direct-to-consumer sales of its many brands.
Competition
Currently, in the United States, there are no businesses that can demonstrate or claim a dominant market share of the growing CBD products market. Competition, outside those companies that provide over 0.3 percent THC containing CBD in States where that is allowed under state law, is limited to numerous brands with geocentric distribution footprints.
Overall at this time, there are no major pharmaceutical manufacturing companies marketing general purpose CBD products into the overall CBD market, however, the Company is expecting such an entry in the future. Competition also includes many small regional marketers/packagers of CBD oil containing products that have a limited distribution footprint.
Employees
The Company has 13 full-time employees.
Patents and Trademarks
The Company holds trademark, “PotNetwork”, under U.S. registration number 86860539, registered on January 31, 2017, and expiring on January 31, 2027. It is used by the Company in its own branding and that of its website, PotNetwork.com.
The Company holds no patents, nor at this time, has any patent pending.
Government Regulation
I. The Company’s CBD Products Are Not Subject to the Controlled Substances Act
The Agriculture Improvement Act of 2018 (“AIA” or “the Act”) exempted hemp-derived cannabidiol products (“hemp-derived CBD products”) from the federal Controlled Substances Act (“CSA”). Specifically, the AIA, also known as the Farm Bill of 2018, established a legal definition of “hemp”: the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol [∆-9 THC] concentration of not more than 0.3 percent on a dry weight basis.
The Act amends the CSA to exclude “hemp” from the definition of “marihuana.” It also amended the CSA to exclude THC found in “hemp” from the “tetrahydrocannabinols” listed in Schedule I. Therefore, hemp-derived CBD products that contain less than less than 0.3% of 9∆-THC, such as those marketed by PotNetwork, are not controlled substances under the CSA. These amendments to the CSA took immediate effect on December 20, 2018.
By way of background, the CSA establishes five “schedules” into which a substance with abuse potential may be classified. Substances that fall under any one of the five schedules are subject to various requirements and restrictions enforced by the U.S. Drug Enforcement Administration (“DEA”). The most restrictive is Schedule I, which is reserved for those substances having a high potential for abuse that do not have a currently accepted medical use, and that lack accepted safety for use under medical supervision.
Marijuana has long been classified under Schedule I. Previously, DEA took the position that CBD met the expansive definition of “marijuana”, which made it subject to Schedule I as well. Specifically, DEA created a code number in Schedule I for “marihuana extract,” defined as “an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.” DEA made clear that the agency considered CBD to fall within the definition of “marihuana extract” (and to therefore be a Schedule I substance) if the CBD came from the part of the cannabis plant that is included within the definition of “marijuana.”
The passage of the AIA confirms that hemp-derived CBD products are now excluded from the CSA. As noted above, the AIA amended the definition of “marihuana” as follows:
(A) Subject to subparagraph (B), the term ‘marihuana’ means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds to resin.
(B) The term ‘marihuana’ does not include-
(i) hemp, as defined in section 297A of the Agricultural Marketing Act of 1946.
II. Limits of the AIA
Although the AIA removed “hemp” from the CSA, the Act has limitations.
a. Products containing more than 0.3% of 9∆-THC still subject to the CSA.
Notably, the AIA’s exclusion of “hemp” from the CSA definition of “marihuana” is limited to those parts, derivatives, or extracts of the plant containing less than 0.3% of 9∆-THC. Parts, derivatives, and extracts containing levels of 9∆-THC greater than 0.3% meet the definition of marihuana and are subject to the CSA. Consequently, manufacturers and distributors of CBD products must be prudent with respect to verifying the levels of 9∆-THC in products.
b. Hemp production and cultivation restrictions
The AIA requires the establishment of a shared Federal-state program to regulate the cultivation and production of hemp. The USDA is actively engaged in rulemaking efforts to implement these requirements and state laws are evolving in response. Our Company is not involved in the cultivation or production of hemp; however, we recognize that new rules will impact the industry as a whole and we are closely monitoring the USDA’s rulemaking efforts.
c. Hemp-derived CBD remains subject to FDA regulatory authority
Further, The Federal Food, Drug and Cosmetic Act (“FDCA”) and the AIA authorize the FDA to regulate the marketing and distribution of hemp products in interstate commerce that are intended for consumption, including topical use. Pursuant to its jurisdiction, FDA may regulate hemp as a feed, food, dietary supplement, cosmetic or drug depending on the intended use of the hemp and whether the hemp is otherwise a permissible ingredient for a particular intended use. The AIA expressly preserves the FDA’s authority over “hemp” that is intended to be used as a drug, device, cosmetic, food (including animal food), dietary supplement, or tobacco product.
Generally, hemp-derived CBD products that are intended for ingestion and intended to support the normal function/structure of the body or added as an ingredient in food, may be considered a dietary supplement or conventional food under the FDCA. However, FDA has taken the position through advisory Warning Letters to multiple companies that CBD products are precluded from being marketed as dietary supplements or as food because CBD is subject to statutory exclusions designed to protect the integrity of the drug approval process.
Specifically, the statutory definition of a “dietary supplement” excludes an “article” that has been approved as a drug under section 505 of the FDCA. The term “dietary supplement” also excludes “an article” if (1) it has been authorized for investigation as a new drug; (2) substantial clinical investigations have been instituted on the article and their existence made public; and (3) it was not marketed as a food or dietary supplement prior to being authorized for investigation as a new drug. For purposes of this exclusion, the FDA has interpreted “authorized for investigation as a new drug” to mean that an Investigational New Drug application (“IND”) has been submitted for the active ingredient or active moiety.
FDA has taken the position that hemp-derived CBD cannot be marketed as dietary supplement because a CBD isolate has been approved as a drug, Epidiolex, and prior to approval, was subject to substantial clinical investigations under an IND. Further, FDA has stated that it has not been provided with the evidence needed to overcome this exclusion. The FDA asserts this same position with regard to products marketed as food under a separate, but identical, statutory provision applicable to “food” broadly. As such, FDA takes the position that hemp-derived CBD products intended for ingestion may be adulterated.
That being said, FDA has yet to take enforcement action against CBD products and has initiated a regulatory process to determine whether there is a regulatory pathway to permit the marketing of these products. Indeed, FDA in recognizing the significant increase in hemp-derived CBD products on the market, the Agency held a public meeting on May 31, 2019, requesting scientific information and data regarding the safety, manufacturing, product quality, marketing, labeling, and sale of products containing hemp-derived CBD. It further requested that comments be filed with the agency by July 2, 2019. This meeting and request for comments signaled FDA’s intent to consider various regulatory options for CBD products, including but not limited to (1) requiring companies to seek approval to market such product; (2) issuing regulations setting forth the conditions which such products may be marketed in food and dietary supplements; or (3) prohibiting the use of hemp-derived CBD in foods and dietary supplements. With that said, there is significant regulatory uncertainty around this category which makes it difficult to predict the likely outcome of this process FDA has initiated. As of the date of this Report, the FDA has not issued subsequent regulatory guidelines.
d. Hemp-derived CBD products are subject to regulation on the state level.
Although the AIA provided clarity regarding the status of hemp-derived CBD under the federal CSA, the AIA did not address the myriad of state laws and regulations governing such products. For example, hemp-derived CBD still meets the definition of a controlled substance under certain laws.
FDA Warning Letter
On March 28, 2019, PotNetwork Holdings received a Warning Letter from the U.S. Food and Drug Administration related to its marketing of CBD products.
(i) The FDA alleged that some claims made on the Diamond CBD website suggested that the products were intended to cure, mitigate, treat, or prevent disease, the definition of a drug under section 201(g)(1)(B) of the FDCA, and as such, the Company was establishing said products as unapproved new drugs. These claims included references to clinical studies on CBD demonstrating health benefits for patients with certain diseases, including Alzheimer’s and diabetes. Based on these claims, the FDA considered the products to be unapproved new drugs in violation of the FDCA.
(ii) The FDA alleged that an such product cannot lawfully be marketed as a dietary supplement because the FDA has concluded that CBD is excluded from the definition of a dietary supplement. Specifically, the section 201(ff)(3)(B)(i) and (ii) of the FDCA excludes from the definition of “dietary supplement” articles that are active ingredients in drugs or for which substantial investigations as a drug have commenced if the substances were not marketed as food or dietary supplements prior to the approval of the drug or commencement of the investigation. Since CBD isolate is the active ingredient in the approved drug, Epidiolex, and substantial clinical investigations have been conducted under IND. FDA has taken the position that there is no evidence that CBD was marketed as a food and dietary supplement prior to the approval or investigation of these drugs and, therefore, any hemp-derived CBD product does not meet the definition of a dietary supplement. Consequently, based on their analysis, any such products may violate the FDCA.
(iii), 301(ll) of the FDCA prohibits food from containing an approved drug or drug for which substantial clinical investigations have been instituted unless such drug was marketed as food prior to the approval of the drug or institution of the clinical investigation. As discussed, FDA has taken the position that there is no evidence that CBD was marketed as food prior to substantial clinical investigations on CBD conducted under IND were made public. Moreover, the Warning Letter states that the Diamond CBD products containing a Nutrition Facts panel are not appropriately marketed because the presence of CBD excludes the product from being marketed as a food. Consequently, such products may violate the FDCA.
In 2019, the Company took significant steps to respond to FDA concerns enumerated in its Warning Letter. The Company removed all claims from its Diamond CBD website that were referenced in the Warning Letter that suggested or implied that any of its CBD products is intended to be used as a drug. The Company also acted swiftly and removed other claims in an effort to ensure compliance with the FDCA and be responsive to FDA’s concerns.
Additionally, on April 30, 2019 independent counsel for the Company provided a written response to the Warning Letter identifying the changes implemented by the Company and responding to the allegations related to CBD prohibition in a dietary supplement. As of date of this filing, the Company has not received any response from the Agency. Nor has it been the subject of any other enforcement action.
Importantly, the Warning Letter did not state or imply any consumer or other complaint relating to any of Company’s products in terms of their purity, quality, or safety.
Emerging Growth Company Status
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (JOBS Act). For as long as we are an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding advisory “say-on-pay” votes on executive compensation and shareholder advisory votes on golden parachute compensation. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year during which we have total annual gross revenues of $1 billion or more; (ii) the last date of the fiscal year following the fifth anniversary of the date of the first sale of common stock under this registration statement; (iii) the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; and (iv) the date on which we are deemed to be a “large accelerated filer” under the Exchange Act. We will be deemed a large accelerated filer on the first day of the fiscal year after the market value of our common equity held by non-affiliates exceeds $700 million, measured on January 1st.
We cannot predict if investors will find our common stock less attractive to the extent, we rely on the exemptions available to emerging growth companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
A Company that elects to be treated as an emerging growth company shall continue to be deemed an emerging growth company until the earliest of (i) the last day of the fiscal year during which it had total annual gross revenues of $1,000,000,000 (as indexed for inflation), (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of common stock under this registration statement; (iii) the date on which it has, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which is deemed to be a ‘large accelerated filer’ as defined by the SEC, which would generally occur upon it attaining a public float of at least $700 million.

---

ITEM 1A. RISK FACTORS
Item 1A. RISK FACTORS
An investment in our common stock involves a high degree of risk. Our business and results of operations could be seriously harmed by any of the following risks described herein or as may arise during the course of business.
We are unable to predict the ongoing impact of COVID-19 on our Company.
The overall effect of the travel and other restrictions in place to stop the spread of COVID-19 has had, and continues to have, a significant impact on the overall economy, on retail sales, consumer discretionary spending and our business. Throughout calendar 2020, the Company experienced chronic business and supply chain interruptions which negatively impacted business results and profitability. Moreover, a portion of our business plan is related to the distribution and sale of our products to retail shops which have been negatively impacted by the COVID-19 pandemic. To date in 2021, we continue to experience business and supply chain interruptions as well as strictures on retail distribution and sales. Going forward for 2021 and beyond, we cannot predict what the ongoing negative impact of the COVID-19 pandemic will be, nor how long such effects will last. Additionally, because of the COVID-19 pandemic’s effect on capital markets, the Company may find it difficult to raise additional funds as needed on terms acceptable to us which we will be need to execute our overall, ongoing business plan.
The continuing COVID-19 pandemic presents an ongoing risk to the Company’s ability to continue as a going concern. Moreover, the risk of illness from COVID-19 or its variants to our officers and directors, management and accounting personnel, creates a risk to the efficiency of our existing internal control system and processes, and therefore, increases the risk of material misstatement in the preparation and presentation of our financial data and statements.
Our industry may become subject to expanded regulation and increased enforcement by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC)
The FDA under the Federal Food, Drug, and Cosmetic Act regulates the formulation, manufacturing, packaging, labeling, and distribution of food, dietary supplements, drugs, cosmetic, medical devices, biologics, and tobacco products. Our CBD products are not intended to be drugs. Accordingly, we have not been required to obtain FDA approval for our existing CBD products. Moreover, the regulatory status of CBD products is in a state of flux as FDA attempts to determine the appropriate manner in which to regulate these products. Thus, the regulatory approach is still evolving, meaning we may be required to seek FDA’s approval to market food, dietary supplements and other products containing CBD. It is also possible that FDA may simply issue a regulation setting forth the conditions in which such products may be marketed, or it may simply prohibit certain of these products. However, because FDA’s regulatory process development is in its infancy, we cannot predict the likely outcome. In addition, the FTC under the Federal Trade Commission Act (“FTC Act”) requires that product advertising is truthful, substantiated and non-misleading. We believe that our advertising meets these requirements. However, the FTC may bring a challenge at any time to evaluate our compliance with the FTC Act.
As disclosed herein, our Company received a Warning Letter from the FDA and the FTC regarding the advertising and labeling claims for our products. FDA also takes the position that certain ingestible products containing CBD may only be marketed if approved as a “drug.” Although we dispute the issues identified by FDA and FTC, we have adjusted the advertising and labeling claims raised in the letter to be in material compliance with the FDCA and the FTC Act.
Despite our corrective actions in response to the Warning Letter, as a Company regulated by the FDA and the FTC, we may be subject to enforcement actions by either agency. Enforcement actions by FDA may include a seizure of our products, an injunction issued by a federal court preventing us from selling our products, civil monetary penalties, or, in egregious circumstances, criminal prosecution. The potential enforcement actions that may be taken by the FTC include an injunction in a Federal District Court, an Administrative Cease and Desist Order, or civil monetary penalties. Finally, it is possible that FDA may decide to prohibit the use of CBD in foods and/or dietary supplements. Similar action could likewise occur through state proceedings.
We have a limited operating history and operate in a new industry, and we may not succeed.
The consumer products’ business is a highly competitive and risky business, and such competition from companies much bigger than us could adversely affect our operating results.
We compete with many national, regional and local businesses. We could experience increased competition from existing or new companies in our channel, which could create increasing pressures to grow ours. If we are unable to maintain our competitive position, we could experience downward pressure on prices, lower demand for our products, reduced margins, the inability to take advantage of new business opportunities and the loss of channel share, which would have an adverse effect on our operating results. Other factors that could affect our business are:
●
Consumer tastes
●
National, regional or local economic conditions
●
Disposable purchasing power
●
Demographic trends; and
●
The price of special ingredients that are utilized for our products and other price fluctuation in costs to manufacture our products.
Increases in the cost of ingredients, labor and other costs could adversely affect our operating results.
Our principal products contain CBD oil and its derivatives. Increases in the cost of ingredients in our products could have a material adverse effect on our operating results. Significant price increases, market conditions, weather, acts of God and other disasters could materially affect our operating results. An increase in our operating costs could adversely affect our profitability. Factors such as inflation, increased labor and employee benefit costs and increased energy costs may adversely affect our operating costs. Many of the factors affecting costs are beyond our control and we may not be able to pass along these increased costs to our customers.
We do not have long-term contracts with many of our suppliers, and as a result they could seek to increase prices or fail to deliver.
We typically do not rely on written contracts or long-term arrangements with our suppliers. Although we have not experienced significant problems with our suppliers, our suppliers may implement significant price increases or may not meet our requirements in a timely fashion, if at all. The occurrence of any of the foregoing could have a material adverse effect on our operating results.
Any prolonged disruption in the operations of any of our supplier’s packaging facilities could harm our business.
Any prolonged disruption for any reason to the operations of any of our supplier’s facilities that perform our packaging, whether due to technical or labor difficulties, destruction or damage to the facility, real estate issues or other reasons, could result in increased costs and reduced revenues and our profitability and business results could be harmed.
Loss of key personnel or our inability to attract and retain new qualified personnel could hurt our business and inhibit our ability to operate and grow successfully.
Our ability to successfully grow our brands depends on our ability to attract and retain professionals with talent, integrity, enthusiasm and loyalty to our corporate team. If we are unable to attract or retain key personnel, our profitability and growth potential could be harmed.
We may not be able to adequately protect our intellectual property, which could harm the value of our brand and branded products and adversely affect our business.
We depend in large part on our brands and branded products as well as on our proprietary processes and believe that they are vital to our business. We rely upon copyrights and trade secrets and other intellectual property rights to protect our brands and individual branded products. The success of our business depends on our continued ability to use our existing intellectual property rights in order to increase brand awareness and further develop our brands sales in the markets we serve. We have successfully registered one trademark, “PotNetwork” in the United States but have faced difficulty with the U.S. Patent and Trademark Office in our attempts at additional registrations due to the legal status of products we have sought to register. As a result, we may not be able to adequately protect our intellectual property from liability connected to a third-party claim of trademark infringement, trademark dilution or unfair competition. We may from time to time be required to institute litigation to enforce our intellectual property rights including for our trade secrets. Such litigation could result in substantial costs and diversion of resources and could negatively affect our sales and results of operations.
Our annual and quarterly financial results are subject to significant fluctuations depending on various factors, many of which are beyond our control, which could adversely affect our ability to satisfy our debt obligations as they become due.
Our sales and operating results can vary significantly from quarter to quarter and year to year depending on various factors, many of which are beyond our control. These factors include:
●
Variations in the timing and volume of our sales
●
The timing of expenditures in anticipation of future sales
●
Sales promotions by us and our competitors
●
Changes in competitive and economic conditions generally
●
Business disruptions
Consequently, our results of operations may decline quickly and significantly in response to changes in order patterns or rapid decreases in demand for our products. We anticipate that fluctuations in operating results will continue in the future. The Company’s operating results may vary. We may incur net losses. The Company expects to experience variability in its revenues and net profit. While we intend to implement our business plan to the fullest extent we can, we may experience net losses. Factors expected to contribute to this variability include, among other things:
●
The general economy
●
The regulatory environment for our products
●
Climate, seasonality and environmental factors
●
Consumer demand
●
Transportation costs
●
Competition in products
You should further consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages. For example, unanticipated expenses, problems, and technical difficulties may occur and they may result in material delays in the operation of our business, in particular with respect to our new products. We may not successfully address these risks and uncertainties or successfully implement our operating strategies. If we fail to do so, it could materially harm our business to the point of having to cease operations and could impair the value of our common stock to the point investors may lose their entire investment.
We may require additional capital to finance our operations in the future, but that capital may not be available when it is needed and could be dilutive to existing stockholders.
We may require additional capital for future operations. We plan to finance anticipated ongoing expenses and capital requirements with funds generated from the following sources:
●
Cash provided by operating activities
●
Available cash and cash investments
●
Capital raised through debt and equity offerings
Current conditions in the capital markets are such that traditional sources of capital may not be available to us when needed or may be available only on unfavorable terms. Our ability to raise additional capital, if needed, will depend on conditions in the capital markets, economic conditions and a number of other factors, many of which are outside our control. Accordingly, we cannot assure you that we will be able to successfully raise additional capital at all or on terms that are acceptable to us. If we cannot raise additional capital when needed, it may have a material adverse effect on our liquidity, financial condition, results of operations and prospects. Further, if we raise capital by issuing stock, the holdings of our existing stockholders will be diluted.
If we raise capital by issuing debt securities, such debt securities would rank senior to our common stock upon our bankruptcy or liquidation. In addition, we may raise capital by issuing equity securities that may be senior to our common stock for the purposes of dividend and liquidating distributions, which may adversely affect the market price of our common stock. Finally, upon bankruptcy or liquidation, holders of our debt securities and shares of preferred stock and lenders with respect to other borrowings will receive a distribution of our available assets prior to the holders of our common stock. Additional equity offerings may dilute the holdings of our existing stockholders or reduce the market price of our common stock, or both.
Our stock price has been extremely volatile, and our common stock is not listed on a national stock exchange; as a result, stockholders may not be able to resell their shares at or above the price paid for them.
The market price of our common stock has been historically volatile and could be subject to significant fluctuations due to changes in sentiment in the market regarding our operations or business prospects, among other factors. Further, our common stock is not listed on a national stock exchange; we intend to list the common stock on a national stock exchange once we meet the entry criteria. An active public market for our common stock currently exists on the OTC market but may not be sustainable. Therefore, stockholders may not be able to sell their shares at or above the price they paid for them.
Among the factors that could affect our stock price are:
●
Industry trends and the business situation of our suppliers
●
Actual or anticipated fluctuations in our quarterly financial and operating results and operating results that vary from the expectations of our management or of securities analysts and investors
●
Failure to meet the expectations of the investment community and changes in investment community recommendations or estimates of our future operating results
●
Announcements of strategic developments, acquisitions, dispositions, financings, product developments and other materials events by us or our competitors
●
Regulatory and legislative developments
●
Litigation and other legal or administrative issues
●
General market conditions
●
Other domestic and international macroeconomic factors unrelated to our performance
●
Changes in key personnel
Sales by our stockholders of a substantial number of shares of our common stock in the public market could adversely affect the market price of our common stock.
A substantial portion of our total outstanding shares of common stock may be sold into the market at any time, or a substantial portion of our total outstanding shares of preferred stock may be converted to common stock and sold into the market at any time. Some of these shares are owned by the management of the Company, and we believe that such holders have no current intention to either convert their preferred stock into common stock or to sell a significant number of shares of their common stock into the market. If all of the major stockholders were to decide to sell large amounts of stock over a short period of time such sales could cause the market price of our common stock to drop significantly, even if our business is performing well.
Our financial statements may not be comparable to those of other companies.
Pursuant to Section 107(b) of the JOBS Act, we have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of The JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result, our financial statements may not be comparable to companies that comply with public company effective dates, and our stockholders and potential investors may have difficulty in analyzing our operating results if comparing us to such companies.
The success of our new and existing products and services is uncertain.
We cannot assure you that we will achieve market acceptance for all of our products, or of new products that we may offer in the future. Moreover, these new products may be subject to significant competition with offerings by new and existing competitors. In addition, new products and enhancements may pose a variety of challenges and require us to attract additional qualified employees. The failure to successfully develop and market these new products or enhancements could seriously harm our business, financial condition and results of operations.
Our business is dependent upon continued market acceptance by consumers.
We are substantially dependent on continued market acceptance of our products by consumers. Although we believe that our products in the United States are gaining increasing consumer acceptance, we cannot predict that this trend will continue in the future.
We may be unable to successfully manage future growth.
The growth of any business places substantial strain on managerial, operational, financial and other resources. If we are able to continue expanding our operations, such growth will require additional resources. In addition to such growth placing increased strain on our management, operations, financial and other resources, such growth will require that we train, motivate, and manage additional employees and other professionals. Moreover, we will need to expand the scope of our infrastructure and our physical resources. In the event of such growth, any failure to expand these areas and implement appropriate procedures and controls in an efficient manner and at a pace consistent with our business objectives could have a material adverse effect on our business and results of operations.
Any future litigation could have a material adverse impact on our results of operations, financial condition and liquidity, particularly since we do not currently have director and officer (“D&O”) insurance. Our lack of insurance may also make it difficult for us to retain and attract talented and skilled directors and officers. While we intend to apply for D&O insurance, we cannot guarantee that such application will be accepted.
Despite our significant efforts in product quality control, we face risks of litigation from customers and others in the ordinary course of business, which may divert our financial and management resources. Any adverse litigation or publicity may negatively impact our financial condition and results of operations.
Claims of illness or injury relating to product quality or handling are common in the consumer products industry. While we believe our processes and high standards of quality control will minimize these instances, there is always a risk of occurrence, and so despite our best efforts to regulate quality control, litigation may occur. In that event, our financial condition, operating results and cash flows could be harmed.
From time to time we may be subject to litigation, including potential stockholder derivative actions. Risks associated with legal liability are difficult to assess and quantify, and their existence and magnitude can remain unknown for significant periods of time. To date, we have no directors’ and officers’ liability (“D&O”) insurance to cover such risk exposure for our directors and officers. Such insurance generally pays the expenses (including amounts paid to plaintiffs, fines, and expenses including attorneys’ fees) of officers and directors who are the subject of a lawsuit as a result of their service to the Company. While we intend to attempt to obtain such insurance, there can be no assurance that we will be able to do so at reasonable rates or at all, or in amounts adequate to cover such expenses should such a lawsuit occur. While neither Colorado law nor our articles of incorporation or bylaws require us to indemnify or advance expenses to our officers and directors involved in such a legal action, we expect that we would do so to the extent permitted by Colorado law. Without D&O insurance, the amounts we would pay to indemnify our officers and directors should they be subject to legal action based on their service to the Company could have a material adverse effect on our financial condition, results of operations and liquidity. Further, our lack of D&O insurance may make it difficult for us to retain and attract talented and skilled directors and officers, which could adversely affect our business.
Our prior operating results may not be indicative of our future results.
You should not consider prior operating results with respect to revenues, net income or any other measure to be indicative of our future operating results. The timing and amount of future revenues will depend almost entirely on our ability to sell our products to new customers. Our future operating results will depend upon many other factors, including:
●
The level of product and price competition,
●
Our success in expanding our distribution network and managing our growth,
●
Our ability to develop and market product enhancements and new products,
●
The timing of product enhancements, activities of and acquisitions by competitors,
●
The ability to hire additional qualified employees, and
●
The timing of such hiring and our ability to control costs.
Our current Board of Directors consists of only two individuals
Gary Blum, Esq., and Lee Lefkowitz, our President and CEO, are the sole members of the Board of Directors.
We only have one outside Director which could create a conflict of interests and pose a risk from a corporate governance perspective.
Our Board of Directors consists of only two directors, only one of whom is an outside or independent director. The lack of independent directors may prevent the Board from being independent from management in its judgments and decisions and its ability to pursue the Board responsibilities without undue influence. For example, an independent board can serve as a check on management, which can limit management taking unnecessary risks. Furthermore, the lack of independent directors creates the potential for conflicts between management and the diligent independent decision-making process of the Board. Furthermore, our lack of outside directors deprives our company of the benefits of various viewpoints and experience when confronting the challenges we face. With only a single independent director sitting on the Board of Directors, it will be difficult for the Board to fulfill its traditional role as overseeing management.
Requirements associated with being a reporting public company require significant company resources and management attention.
We filed a Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”). Since the Form 10 became effective, we have been subject to the reporting requirements of the Exchange Act and the other rules and regulations of the SEC relating to public companies. We are working with independent legal, accounting and financial advisors to identify those areas in which changes should be made to our financial and management control systems to manage our growth and our obligations as an SEC reporting company. These areas include corporate governance, internal control, internal audit, disclosure controls and procedures and financial reporting and accounting systems. We have made, and will continue to make, changes in these and other areas, including our internal control over financial reporting. However, we cannot provide assurances that these and other measures we may take will be sufficient to allow us to satisfy our obligations as an SEC reporting company on a timely basis.
In addition, compliance with reporting and other requirements applicable to SEC reporting companies will create additional costs for the Company and will require the time and attention of management and may require the hiring of additional personnel and legal, audit and other professionals. We cannot predict or estimate the amount of the additional costs we may incur, the timing of such costs or the impact that our management’s attention to these matters will have on our business.
Our preferred shareholders have voting control.
The holders of our Series A Preferred Stock have voting control over the Company. As a result, they have the ability to control substantially all matters submitted to our stockholders for approval including:
●
Election of our board of directors;
●
Removal of any of our directors;
●
Amendment of our articles of incorporation or bylaws; and
●
Adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us.
In addition, each share of Class A preferred stock is convertible into 0.01% of the total number of shares of Common Stock outstanding at the Conversion Time. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
Based on the preceding and upon a total quantity of issued and outstanding shares as of September 27, 2021 of 909,974,924, each share of Class A preferred stock is convertible into 90,997 shares of common stock. As a result, if each of the two Class A preferred shareholders listed were able to convert 100% of each’s Class A preferred stock, Kevin Hagen, who holds 20,742 Class A preferred shares, would receive 1,887,459,774 shares of common stock; and Elinor Taieb, who holds 13,547 Class A preferred shares, would receive 1,232,736,359 shares of common stock.
Our preferred stock has rights senior to those of our common stock which could adversely affect holders of common stock.
Our articles of incorporation give our Board of Directors the authority to issue additional series of preferred stock without a vote or action by our stockholders. The Board also has the authority to determine the terms of preferred stock, including price, preferences and voting rights. The rights granted to holders of preferred stock in the future may adversely affect the rights of holders of our common stock. Any such authorized class of preferred stock may have a liquidation preference - a pre-set distribution in the event of a liquidation - that would reduce the amount available for distribution to holders of common stock or superior dividend rights that would reduce the amount of dividends that could be distributed to common stockholders. In addition, an authorized class of preferred stock may have voting rights that are superior to the voting right of the holders of our common stock.
We are an emerging growth company and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.
We are an emerging growth company, as defined in the JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting requirements applicable to other public companies, but not to emerging growth companies, including, but not limited to, a requirement to present only two years of audited financial statements, an exemption from the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act, reduced disclosure about executive compensation arrangements pursuant to the rules applicable to smaller reporting companies and no requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements, although some of these exemptions are available to us as a smaller reporting company (i.e. a company with less than $75 million of its voting equity held by affiliates). We have elected to adopt these reduced disclosure requirements. We cannot predict if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If some investors find our common stock less attractive as a result of our choices, there may be a less active trading market for our common stock and our stock price may be more volatile.
We do not expect to pay any cash dividends in the foreseeable future.
We intend to retain our future earnings, if any, in order to reinvest in the development and growth of our business and, therefore, do not intend to pay dividends on our common stock for the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, and such other factors as our board of directors deems relevant. Accordingly, investors may need to sell their shares of our common stock to realize a return on their investment, and they may not be able to sell such shares at or above the price paid for them.
We can sell additional shares of common stock without consulting stockholders and without offering shares to existing stockholders, which would result in dilution of existing stockholders’ interests in the Company and could depress our stock price.
Our Articles of Incorporation, as amended on February 5, 2020, authorize 1,500,000,000 shares of common stock, of which 909,974,924 are outstanding as of September 27, 2021. Our Articles of Incorporation, as amended on February 5, 2020, also authorize 50,000 shares of series A preferred stock, of which 34,289 are outstanding on September 27, 2021. Moreover, our Board of Directors is authorized to issue additional shares of our common stock and preferred stock. Although our Board of Directors intends to utilize its reasonable business judgment to fulfill its fiduciary obligations to our then existing stockholders in connection with any future issuance of our capital stock, the future issuance of additional shares of our common stock or preferred stock convertible into common stock would cause immediate, and potentially substantial, dilution to our existing stockholders, which could also have a material effect on the market value of the shares.
Because we are subject to “penny stock” rules, the level of trading activity in our stock may be reduced.
Broker-dealer practices in connection with transactions in “penny stocks” are regulated by penny stock rules adopted by the Securities and Exchange Commission. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on some national securities exchanges). The penny stock rules require a broker-dealer to deliver to its customers a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market prior to carrying out a transaction in a penny stock not otherwise exempt from the rules. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and, if the broker-dealer is the sole market maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, broker-dealers who sell these securities to persons other than established customers and “accredited investors” must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. Consequently, these requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security subject to the penny stock rules.
Financial Industry Regulatory Authority (FINRA) sales practice requirements may also limit your ability to buy and sell our stock, which could depress our share price.
FINRA rules require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares, depressing our share price.

---

ITEM 1B. UNRESOLVED STAFF COMMENTS
ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.

---

ITEM 2. PROPERTIES
ITEM 2. PROPERTIES
The Company uses offices provided by its Kevin Hagen, Esq., a principal shareholder, and incurs no charge for their use.

---

ITEM 3. LEGAL PROCEEDINGS
ITEM 3. LEGAL PROCEEDINGS
First Capital Venture Co. v. Thunder Energies Corporation, f/k/a Thunder Fusion Corporation, CCJ ACQUISITION CORP d/b/a the Hemplug, the Hemplug, LLC, Nature Consulting, LLC, et al., Case No. CACE 20-019111. On November 3, 2020, First Capital Venture d/b/a Diamond CBD, Ltd., filed its 5-count verified Complaint seeking injunctive and declaratory relief as well as damages against Defendants. Specifically, the verified Complaint alleges the Defendants violated Florida’s Uniform Trade Secrets Act as well as allegations that the Defendants tortiously interfered with a contractual or business relationship of First Capital Venture. On February 17, 2021, Defendants filed their answer and affirmative defenses. On March 5, 2021, First Capital Venture filed its Motion for Order to Show Cause in which it seeks sanctions for Defendants’ failure to comply with the Court’s Order compelling Defendants to provide responses to Plaintiff’s discovery requests. At a hearing on March 29, 2021, the judge deferred ruling on First Capital Venture’s Motion for Order to Show Cause. Immediately following the Show Cause Hearing, the Defendants filed response to Plaintiff’s Motion for Order to Show Cause and the Plaintiff filed a memorandum in support. Prior to the Motion for Order to Show Cause, on February 17, 2021, Defendants furnished a request for production of documents to Plaintiff. Within the time prescribed by the Florida Rules of Civil Procedure to respond to the Defendants’ request for production, Plaintiff filed a motion for extension of time to respond to the request for production of documents on March 16, 2021. Defendants filed a motion to compel the responses for the Defendants’ Request for Production of Documents to Plaintiffs, however, there is no pending Order compelling the Plaintiff to provide the discovery as of the date of this report. On April 28, 2021, the Judge signed an Order which compelled the Defendants, Yogev Shvo and Orel Ben Simon, before the Honorable Court to show cause as to why the Defendants should not be held in contempt of Court for failure to properly respond to outstanding discovery. On May 10, 2021, a special set hearing occurred in which the Judge deferred ruling on the Motion for Order to Show Cause. The case remains ongoing.
First Capital Venture Co. v. T1 Payments, LLC et al., Case No. CACE-20-006914, UCN 062020CA006914AXXXCE, 17th Judicial Circuit in and for Broward County, Florida. On April 22, 2020, First Capital Venture, a subsidiary of the Company filed an 8-count Complaint against the its previous merchant processor seeking the return of $649,311.73 being held by the merchant processor and for damages related to this processor ceasing to accept MasterCard payments from the Company’s customers for the purchase of the Company’s products. The Company is seeking declaratory relief as well as damages against the Defendant. Specifically, the Complaint alleged the Defendant breached the contract between the parties, sought violations of Florida Statute § 772.11 (Civil Remedy for Theft), replevin, and fraud. On August 4, 2020, the Court granted a motion to transfer the case to Nevada where it will be filed per the merchant processing agreement. As a result, the lawsuit was dismissed without prejudice to be filed in the appropriate jurisdiction per the processing agreement.
Therefore, on May 14, 2021, First Capital Venture Co., filed an eight-count complaint against T1 Payments, LLC, Donald Kasdon and Does 1 through 10, in District Court, Clark County, Nevada, under case number: A-21-834626-B. The 8-count Complaint against the previous merchant processor seeks the return of $649,311.73 being held by the merchant processor and seeks damages related to this processor ceasing to accept MasterCard payments from the Company’s customers for the purchase of the Company’s products. The Company is seeking declaratory relief as well as damages against the Defendants. Specifically, the Complaint alleged the Defendants breached the contract between the parties, fraud, conversion and unjust enrichment. To help expediate the litigation of this case, Company’s counsel sought a more specialized type of proceeding by requesting the matter be heard in business court. The Company is continuing to work with counsel in California and Nevada to resolve this matter.
Dr. Bomi Joseph v. PotNetwork Holdings, Inc. et al, Case No. 19STCV15296, Superior Court of California - Los Angeles County for Los Angeles Judicial District. Plaintiff alleges that defendants published a report on or about February 22, 2019, about him on its website, www.potnetworkcom, without his consent, acknowledgement and approval, which report is of concern to the Plaintiff. Moreover, the report was picked up and re-published on numerous other websites without permission of the defendants. The Plaintiff alleges that the report defamed him and that it continues to be published by third party websites although already retracted and taken down by the defendants. The Plaintiff and the Company have entered into settlement negotiations.
Potter v. PotNetwork Holdings, Inc., Diamond CBD, Inc., and First Capital Venture Co., CASE NO.: 19-24017-CV-SCOLA, US District Court for the Southern District of Florida. Plaintiff alleged that she purchased certain products from Diamond CBD that contained levels of CBD that were less than the amount stated on the packaging and sought class action status. The Company and its subsidiaries settled the matter at mediation on July 14, 2020. The parties completed the final documentation of the settlement and the case was dismissed on August 27, 2020. Pursuant to the settlement agreement the Company agreed to issue a $10 voucher to purported class members, pay the named plaintiff $5,000 and pay the law firms that brought the suit $200,000 in legal fees to be paid over 30 months, secured by a pledge of shares of the common stock of PotNetwork Holdings, Inc.
Viral Vapes, LLC, v. CBD, LLC, CASE NO.: 20-C-07896-S6, filed in the State Court of Gwinnett County, Georgia, on February 2, 2021. Plaintiff alleges that the Defendant breached a contract for the resale of its goods which were returned to the Defendant for credit. Plaintiff seeks compensatory damages in an amount to be proved at trial, but not less than $34,825, the purchase price of the goods purchased and returned, plus interest and reasonable attorney’s fees incurred in prosecuting this claim. The Company is contesting the allegations. The case is ongoing.
In addition to the above, Company had been involved in the following legal proceedings, each since dismissed as the result of a respective settlement agreement, and each of which is specific to each plaintiff suing the Company based upon the convertibility of a promissory note. In each case the Company had contested the validity of the request for conversion of shares pursuant to each such note (each referred to as a “Note”). The following are the case references to each case filed by each of the plaintiffs (collectively, the “Plaintiffs”):
●
Mammoth West Corporation v PotNetwork Holdings Inc., Case No. 17 CH 778, 19th Circuit Court of Lake County, IL. Filed May 26, 2017.
●
Southridge Partners II Limited Partnership vs. SND Auto Group, Inc., Case No. 3:17-cv-01925 US District Court for the District of Connecticut, filed January 5, 2018.
●
J. P. Carey Limited Partners, L.P. v. PotNetwork Holdings, Inc., Case No.3:18-CV-00873-WWE, US District Court for the District of Connecticut, filed May 24, 2018.
Each Plaintiff had filed a civil complaint with regard to their rights to convert a specific Note. In each case, the Note was issued not by the Company, but by its predecessor issuer, SND Auto Company Inc. (which predecessor issuer had changed its name before changing it back to SND Auto Group, Inc.). Each Note was issued by SND Auto Company Inc., respectively on June 13, 2016 to Mammoth West Corporation and on July 18, 2016 to Southridge Partners II Limited Partnership, for money paid to SND Auto Company Inc., at a time when SND Auto Company Inc. was the public entity, with sole operations in the automotive industry. (Plaintiff, J. P. Carey Limited Partners, L.P., on March 1, 2018, was a subsequent purchaser of a portion of the Southridge Partners II Limited Partnership Note and conversion rights connected to the amount purchased, which it then attempted to convert on the pre-reorganization terms and conditions of the Note, as more fully defined below.)
Subsequent to the issuance of the Notes, on March 14, 2017, SND Auto Company Inc. had engaged in a holding company reorganization whereby SND Auto Company Inc., became a subsidiary of the public entity. The holding company reorganization was an express condition of a private company, First Capital Venture Holdings Co., whose acquisition was the principal reason for the reorganization.
Each Plaintiff had sought to convert into shares of the post reorganization Company, at a conversion price of a fraction of a penny per share, based on SND Auto Group, Inc.’s share price prior to the reorganization. The Company disputed the conversion amounts presented by the Plaintiffs
The relief that had been sought by each Plaintiff in each case is as follows:
●
Mammoth West Corporation: Issuance of the shares per each of its conversion notices per the original terms of its Note, reasonable attorneys’ fees and reimbursement of court costs, and such other and further relief as the court deems appropriate.
●
Southridge Partners II Limited Partnership: Damages of at least $743,150, interest, punitive damages, a mandatory injunction seeking specific performance, reasonable attorneys’ fees and reimbursement of court costs, and such other and further relief as the court deems appropriate.
●
J. P. Carey Limited Partners, L.P.; Damages of at least $573,890, interest, punitive damages, a mandatory injunction seeking specific performance, reasonable attorneys’ fees and reimbursement of court costs, and such other and further relief as the court deems appropriate.
On August 17, 2020, JP Carey Limited Partners L.P. and the Company came to a settlement, whereby the Company agreed to issue 28 million shares of the Company’s common stock to JP Carey, valued at $379,752, subject to certain leak out provisions. The case has subsequently been dismissed.
On August 27, 2020, the Court dismissed the case brought by Southridge Partners II Limited Partnership for failing to obtain counsel to prosecute the case after the Court’s order to do so. Southridge subsequently sought to refile its claim. On January 21, 2021, the Company and Southridge Partners II Limited Partnership came to a settlement, whereby the Company agreed to issue 38 million shares of the Company’s common stock, valued at $296,400, to an affiliate of Southridge Partners II Limited Partnership, Livingston Asset Management, LLC, subject to certain leak out provisions. The case subsequently was dismissed. However, on July 20, 2021, Southridge Partners II Limited Partnership, and Livingston Asset Management, LLC filed a new complaint in the 17th Judicial Circuit of the State of Florida in and for Broward County Florida, Case CACE-21-014580, claiming default of the settlement reached with the Defendants due the Plaintiff’s inability to deposit their shares. A new settlement is in negotiations.
On October 22, 2020, the Company entered into a settlement agreement with Mammoth Corporation subject to a court approval per a 3(a)10 fairness hearing. On December 11, 2020, the fairness hearing was conducted by the Circuit Court for the Nineteenth Judicial Circuit, Lake County, Illinois, Civil Action No. 17 CH 778. As a result of the court’s approval of the settlement agreement, on December 24, 2020, the Company issued 28,000,000 common shares to Mammoth West Corporation, valued at $315,420, for all indebtedness owed. The case has subsequently been dismissed.

---

ITEM 4. MINE SAFETY DISCLOSURE
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable.
Part II

---

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
Our common stock is quoted on the OTC Pink Sheets Market, an alternative trading system, under the symbol POTN. For the periods indicated, the following table sets forth the high and low closing prices per share of common stock. The below prices represent inter-dealer quotations without retail markup, markdown, or commission and may not necessarily represent actual transactions.
Price Range
Period
High
Low
Year Ending December 31, 2018:
$
$
First Quarter
.0957
.1199
Second Quarter
.413
.194
Third Quarter
.3912
.2206
Fourth Quarter
.2761
.0836
Year Ending December 31, 2019:
First Quarter
.1750
.0980
Second Quarter
.1650
.0577
Third Quarter
.1049
$ .0375
Fourth Quarter
.052
.023
Year Ending December 31, 2020:
First Quarter
.374
.0135
Second Quarter
.0169
.0100
Third Quarter
.0176
$ .0121
Fourth Quarter
.0135
.0050
As of September 27, 2021 we had 2,289 shareholders of record of our common stock.
Dividends. We have never declared or paid any cash dividends on our common stock nor do we anticipate paying any in the foreseeable future. We expect to retain any future earnings to finance our operations and expansion. The payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.
Equity Compensation Plans. We do not have any equity compensation plans.
Penny Stock Considerations
Our shares are considered “penny stocks,” as that term is generally defined in the Securities Exchange Act of 1934 to mean equity securities with a price of less than $5.00. Thus, our shares will be subject to rules that impose sales practice and disclosure requirements on broker-dealers who engage in certain transactions involving a penny stock.
Under the penny stock regulations, a broker-dealer selling a penny stock to anyone other than an established customer must make a special suitability determination regarding the purchaser and must receive the purchaser’s written consent to the transaction prior to the sale, unless the broker-dealer is otherwise exempt.
In addition, under the penny stock regulations, the broker-dealer is required to:
·
Deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the Securities and Exchange Commission relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt;
·
Disclose commissions payable to the broker-dealer and our registered representatives and current bid and offer quotations for the securities;
·
Send monthly statements disclosing recent price information pertaining to the penny stock held in a customer’s account, the account’s value, and information regarding the limited market in penny stocks; and
·
Make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction, prior to conducting any penny stock transaction in the customer’s account.
Because of these regulations, broker-dealers may encounter difficulties in their attempt to sell shares of our common stock, which may affect the ability of holders to sell their shares in the secondary market and have the effect of reducing the level of trading activity in the secondary market. These additional sales practice and disclosure requirements could impede the sale of our securities, if our securities become publicly traded. In addition, the liquidity for our securities may be decreased, with a corresponding decrease in the price of our securities.
Our shares are subject to such penny stock rules and our shareholders will, in all likelihood, find it difficult to sell their securities.

---

ITEM 6. SELECTED FINANCIAL DATA
Item 6. Selected Financial Data.
As a smaller reporting company, we are not required to supply this information.

---

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Overview
The primary business of PotNetwork Holdings, Inc. (“POTN”) is conducted through its primary subsidiary, First Capital Venture Co., whose subsidiary, CBD, LLC (d/b/a Diamond CBD) is engaged in the development and sales of hemp-derived CBD oil containing products. The Company also owns and operates PotNetwork Media Group, Inc., operator of the informational website to the cannabis and CBD industry, PotNetwork.com.
Results of Operations
Results of Operations and Nonrecurring Events during the year ended December 31, 2020 as compared to the year ended December 31, 2019.
For the year ended December 31, 2020 and 2019, we had revenues of $9,680,543 and $15,060,840 respectively. This represents a decrease in revenue of $(5,380,297) or 35.72%. This decrease in revenue was due to a retail distribution contraction as a result of the Covid-19 pandemic, and an overall reduction in direct sales activity specific to the COVID-19 pandemic.
Our Gross Profit from the sale of all products the year ended December 31, 2020 and 2019 was $3,428,205 and $4,816,604 respectively, or a decrease of $(1,388,399) or 28.83%. This decrease was due to the reduction in revenue year-over-year.
Our Net Profit (Loss) for the years ended December 31, 2020 increased to a Loss of $(5,584,669) from a Loss of $(3,367,831) in 2019. The Loss for 2020 is comprised of three distinct items: a loss on operating activities of $(1,877,171) and losses caused by two nonrecurring extraordinary items totaling $ (3,707,497). (There were no nonrecurring event items in 2019.) The operational loss was primarily caused by a reduction in gross margin attributable to a reduction in revenues. The two nonrecurring extraordinary items were (a) a loss attributable to the cost of the issuance of common stock to each of two former debtholders, specific to settlement agreements of long-standing court cases negotiated with each, in the amount of $695,048 in total (see “Item 3. Legal Proceedings”), and (b) a loss from the write off of the amount paid to the drop shipper in the amount of $ (3,012,449). This write-off specific to the drop shipper account includes an adjustment for the reduction in value of inventory beyond its expiration date, and for obsolete or unsalable inventory, both events significantly attributable to a decline in consumer demand because of the Covid-19 pandemic. It also represents an impairment of any remaining value in this asset, which is undergoing internal review. (See note "18 - Critical Audit Matters" in the notes to the financial statements.)
Operating expenses for the twelve-month period ended December 31, 2020 compared to the same period ended December 31, 2019 decreased to $4,930,753 as compared to $7,980,296, a decrease of $3,049,543, or 38.21% attributable to a decrease in advertising and marketing expense from $4,109,951 in the twelve months ended December 31, 2019 to $1,490,713 for the same period in 2020.
Total expenses for the year ended December 31, 2020 were $5,305,376 with interest expense being $374,623 compared to $8,314,435 with interest expense of $334,139 for the comparable period of 2019.
Liquidity and Capital Resources
Assets decreased from $6,124,894 at the Company’s fiscal year end of December 31, 2019 to $709,931 at December 31, 2020. The decrease in the assets is attributable to (a) the reduction over the year of the deposit in the amount of $5,070,696 previously held by our drop shipper on December 31, 2019, to $-0- as the result of utilization of the deposit for fulfillment of 2020 orders, and write-offs including for obsolete/outdated/unsalable inventory of the drop shipper driven by the decline in revenues attributable in part to the Covid-19 pandemic.
Total Liabilities decreased from $5,907,000 as of December 31, 2019 to $5,007,338 as of December 31, 2020. The decrease is mainly attributed to a reduction in the amounts of loans due to third parties. Liabilities include two SBA loans: (a) a Paycheck Protection Program (“PPP”) Loan entered into on 5/6/2020 in the amount of $135,404; and (b) an Economic Injury Disaster Loan (“EIDL”) entered into on 6/18/2020 in the amount of $150,000.
Cash Flow from Operating Activities
Net cash from operations for the year ended December 31, 2020 was $(1,362,590) as compared to $(3,599,572) for the same period in 2019.
Cash Flow from Investing Activities
Net cash provided by investing activities for the year ended December 31, 2020 was $1,069,368 as compared to $2,453,389 for the same period in 2019.
Cash Flow from Financing Activities
Net cash provided by financing activities for the year ended December 31, 2020 was $263,206 as compared to $632,339 for the same period in 2019.
Off-balance sheet arrangements
There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources.

---

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
As a smaller reporting company, we are not required to furnish the information required by Item 7A

---

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Item 8. Financial Statements and Supplementary Data.
The financial statements required to be filed are listed in Item 15 of this Annual Report on Form 10-K and incorporated herein by reference.

---

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
On July 23, 2018, East West Accounting Services (“East-West”) resigned as the independent registered public accounting firm of the Company. The resignation was accepted by the Board of Directors of the Company. East-West stated that the reason for their resignation was the loss of their PCAOB certification as the result of an unrelated matter connected to an audit inadequacy that occurred in an audit for an unrelated company in 2015.
The audit report of East-West on the Company’s financial statements for the fiscal year ended December 31, 2017, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.
During the Company’s 2017 fiscal year and through July 23, 2018, (1) there were no disagreements with East-West on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of East-West, would have caused East-West to make reference to the subject matter of the disagreements in connection with its report, and (2) there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K.
As a result of East-West’s resignation, the Company engaged Manohar Chowdhry & Associates (“MCA”), a PCAOB member firm, as the Company’s independent accountant to audit the Company’s financial statements and to perform reviews of interim financial statements. During the fiscal years ended December 31, 2015, December 31, 2016 and December 31, 2017 through July 23, 2018 neither the Company nor anyone acting on its behalf consulted with MCA regarding (i) either the application of any accounting principles to a specific completed or contemplated transaction of the Company, or the type of audit opinion that might be rendered by MCA on the Company’s financial statements; or (ii) any matter that was either the subject of a disagreement with East-West or a reportable event with respect to East-West.
On January 14, 2019, the Company discharged MCA. The audit report of MCA on the Company’s financial statements for the fiscal year ended December 31, 2017, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.
During the period of the Company’s engagement with MCA, July 23, 2018 through January 14, 2019, (1) there were no disagreements with MCA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of MCA, would have caused MCA to make reference to the subject matter of the disagreements in connection with its report, and (2) there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K.
On January 14, 2019, Yusufali & Associates, LLC, Short Hills, New Jersey 07078 (“Yusufali”), became the Company’s independent accountant to audit the Company’s financial statements and to perform reviews of interim financial statements. During the fiscal years ended December 31, 2016, December 31, 2017 and December 31, 2018, through January 14, 2019, neither the Company nor anyone acting on its behalf consulted with Yusufali regarding (i) either the application of any accounting principles to a specific completed or contemplated transaction of the Company, or the type of audit opinion that might be rendered by Yusufali on the Company’s financial statements; or (ii) any matter that was either the subject of a disagreement with East-West or MCA or a reportable event with respect to East-West or MCA.

---

ITEM 9A. CONTROLS AND PROCEDURES
Item 9A. Controls and Procedures.
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Any “material weakness” in disclosure controls and procedures is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
A material weakness means there is a risk that our financial reports or other filings may contain an error or errors or inaccuracies or may not be submitted on a timely basis.
Any financial internal control system, no matter how well designed, will have inherent limitations including the possibility that the system may have a material weakness or may not prevent or detect misstatements. Therefore, even when internal control systems are deemed effective, they are essentially limited in that they can provide only a reasonable assurance of the validity and reliability of the preparation and presentation of financial statements.
In accordance with U.S. generally accepted accounting principles (“USGAAP”), the Company’s internal control system was developed in order to provide the Company’s management and board of directors with reasonable assurance of the validity and reliability of the Company’s financial reports and any preparation of financial statements used for external purposes
The Company’s management is responsible for establishing and maintaining adequate internal controls over financial reporting. In doing so, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our Chief Executive Officer/Chief Financial Officer and board of directors have each evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the date of the filing of this Report. Based on their summary evaluation, because of the Company’s limited resources and limited number of employees, and absence of an audit committee, the Company has concluded that as of December 31, 2020, its internal control at that time over financial reporting was not effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with USGAAP, which therefore creates a material weakness.
The material weaknesses in our disclosure control procedures are as follows:
1. Lack of formal policies and procedures necessary to adequately review significant accounting transactions. To date, we have utilized third-party independent contractors/accountants for the preparation of our financial statements. Although the financial statements and footnotes are reviewed by our management, we have not had a formal procedure to review significant accounting transactions and the accounting treatment of such transactions. Our third-party independent contractors/accountants are not involved in our day-to-day operations and as a result may not always be provided with relevant financial information on a timely basis that would allow for adequate reporting/consideration of certain transactions.
2. Audit Committee and Financial Expert. As of the date of this Report, the Company does not have an audit committee with a financial expert and, thus, lacks appropriate professional oversight over the financial reporting process and the internal reports generated.
3. Lack of Adequate Processes. As of December 31, 2020, the Company did not have adequate processes in place to ensure thorough timely reviews of accounting and financial reporting matters, which deficiency constitutes a material weakness. This deficiency resulted in the Company’s inability to have a timely closing process that identifies all required adjustments and disclosures necessary for timely filings of reports. In order to help correct this material weakness, the Company is hiring additional accounting personnel with the requisite incremental knowledge to improve the levels of accuracy, disclosure and timely review of accounting and financial reporting matters. However, the Company may experience a delay in achieving such improvements in its internal control and correction of this material weakness until such additional personnel are fully trained in the Company’s accounting policies and procedures. Until such time, this deficiency will continue to exist and there will be a continuing risk of material misstatements in the Company’s financial statements.
The Company intends to initiate measures to remediate the preceding material weaknesses, including, but not necessarily limited to, the following:
●
Formation of an audit committee of the board of directors which includes a financial expert, that together with management, will establish the policies and procedures that will provide the board of directors and management with a formal monthly review process that will, among other things, assure the Company and its management that adequate controls and procedures are in place and being maintained and applied consistently on a monthly basis.
●
Hire additional accounting personnel with the requisite knowledge necessary to apply and implement the Company’s policies and procedures specific to internal control such that reporting is performed on a timely basis.
Exemption from Attestation Report as required by Section 404(b) of the Sarbanes-Oxley Act of 2002
This Annual Report on Form 10-K does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Effective April 27, 2020, the SEC adopted amendments to the “accelerated filer” and “large accelerated filer” definitions in Rule 12b-2 under the Exchange Act. The amendments exclude from the accelerated and large accelerated filer definitions any issuer that is eligible to be a smaller reporting company and that had annual revenues of less than $100 million in the most recent fiscal year for which audited financial statements are available. The Company has determined that it does not meet the accelerated or large accelerated filer definitions as stated. For as long as the Company remains a non-accelerated filer, it intends to take advantage of the exemption permitting it not to comply with the requirement under Section 404(b) of the Sarbanes-Oxley Act of 2002 wherein its independent registered public accounting firm provides an attestation on the management’s assessment of the effectiveness of our internal control over financial reporting.
Changes in Internal Control Over Financial Reporting
During fiscal year 2020, the Company did not undertake any changes in its internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) that have materially affected, or was reasonably likely to materially affect, its internal control over financial reporting.

---

ITEM 9B. OTHER INFORMATION
Item 9B. Other Information.
Share Issuances
On February 6, 2020 the Company issued 27,000,000 common shares to a note holder upon the conversion of $81,000 of indebtedness owed. The common stock issued in the transaction were issued pursuant to the exemption for registration contained in Section 4(a)(2) of the Securities Act of 1933.
On July 8, 2020 the Company issued 24,000,000 common shares to a note holder upon the conversion of $72,000 of indebtedness owed. The common stock issued in the transaction were issued pursuant to the exemption for registration contained in Section 4(a)(2) of the Securities Act of 1933.
On August 20, 2020, the Company issued 28,000,000 common shares to J.P. Carey Limited Partners, L.P., a note holder, under the terms and conditions of a settlement agreement, dated August 15, 2020 for all indebtedness owed. The value of the stock issued under the settlement, $379,752, has been booked in 2020 as a nonrecurring extraordinary expense for accounting purposes.
On October 1, 2020, the Company issued 8,854,782 common shares to a note holder upon the conversion of $75,000 of indebtedness owed. The common stock issued in the transaction were issued pursuant to the exemption for registration contained in Section 4(a)(2) of the Securities Act of 1933.
On November 23, 2020, the Company issued 19,569,479 common shares to a note holder upon the conversion of $100,000 of indebtedness owed. The common stock issued in the transaction were issued pursuant to the exemption for registration contained in Section 4(a)(2) of the Securities Act of 1933.
On December 24, 2020, the Company issued 28,000,000 common shares to Mammoth West Corporation, a note holder, under the terms and conditions of a settlement agreement, dated October 22, 2020 for all indebtedness owed, which settlement was approved on December 11, 2020, by the Circuit Court for the Nineteenth Judicial Circuit, Lake County, Illinois, in Civil Action No. 17 CH 778 following a 3(a) 10 fairness hearing. The value of the stock issued under the settlement, $315,420, has been booked in 2020 as a nonrecurring extraordinary expense for accounting purposes.
On January 13, 2021, the Company issued 35,714,286 common shares to a note holder upon the conversion of $125,000 of indebtedness owed. The common stock issued in the transaction were issued pursuant to the exemption for registration contained in Section 4(a)(2) of the Securities Act of 1933.
On February 10, 2021, the Company issued 38,000,000 common shares to an affiliate, Livingston Asset Management, LLC, of a note holder, Southridge Partners II Limited Partnership, under the terms and conditions of a settlement agreement, dated January 21,2021 for all indebtedness owed. The value of the stock issued under the settlement, $296,400, will be booked in 2021 as a nonrecurring extraordinary expense for accounting purposes.
US v. Kevin Hagen
On April 29, 2021, the United States Attorney for the Northern District of Ohio file an indictment that included charges against Kevin Hagen, the former CEO of the Registrant and the president of First Capital Venture Company. (The Company has not been charged with any wrongdoing and has not been contacted by any law enforcement agency regarding these charges and allegations.) The case remains ongoing.
SBA Loans
On May 5, 2020, the Company received from the SBA, the sum of $135,404 under the Paycheck Protection Program, which is a loan and not repayable provided the lending bank certifies the forgiveness prior to maturity which is two years from making. Interest rate on the loan is 1.0000%. n an email dated Thursday, Aug 26, 2021, TD bank conveyed to the Company that the Paycheck Protection Program loan, in principal value of $138,404, dated 3/5/2020, had been forgiven by the SBA.
On June 16, 2020, the Board of Directors approved the Company’s subsidiary, First Capital Venture, entering into a Disaster Relief Loan from the US Small Business Administration in the amount of $150,000 at an interest rate of 3.75%. The loan is secured by a security interest in all the assets of First Capital Venture and is for working capital purposes.
On March 10, 2021, the Company received from the SBA, the sum of $115,049 under the Paycheck Protection Program, which is a loan and not repayable provided the lending bank certifies the forgiveness prior to maturity which is two years from making. Interest rate on the loan is 1.0000%.
On April 29, 2021, the United States Attorney for the Northern District of Ohio file a superseding indictment that included charges against Kevin Hagen, the former CEO of PotNetwork Holdings, Inc. and the president of its subsidiary First Capital Venture Company.
The Company has not been charged with any wrongdoing and has not been contacted by an law enforcement agency regarding the charges and allegations.
Information Statement; Pending Corporate Actions
On October 27, 2020, by majority vote of the shareholders and the majority approval by the Board of Directors of the Company, the Company filed, and mailed to its shareholders on November 20, 2020, an Information Statement (the “Information Statement”) wherein:
(1) The Company would consolidate its number of issued and outstanding shares of common stock via a reverse stock split in the ratio of 10:1, with any resultant fractional shares rounded up to the next nearest share. (The Company’s preferred shares are not subject to said reverse split.)
(2) Following the reverse split, the Company would amend its Articles of Incorporation, to change the quantity of its authorized shares of common stock from 1,500,000,000 shares to 750,000,000 shares with no change in the number of preferred shares.
(3) The Company would offer to its shareholders of record as of November 25, 2020 (“Rights Offering Record Date”), the right to subscribe for new shares of the Company’s common stock, following the reverse split at an offering price per share to be determined by the Board of Directors after the reverse split. For every 100 shares held as of the Rights Offering Record Date, as adjusted for the reverse split, such shareholder shall be entitled to purchase 10,000 shares, with a minimum purchase of 10,000 shares. And shareholders holding less than 100 shares shall be entitled to purchase the minimum number of shares. The primary purpose and intent of the Rights Offering is to raise funds to increase investible assets, allowing the Company to take advantage of opportunities to grow, including the expansion of our product line and the acquisition of other companies in our industry or related markets.
(4) Shares under the Rights Offering are to be offered pursuant to a registration statement to be filed with the Securities and Exchange Commission (“SEC”) for up to 200,000,000 shares. A preliminary form of the registration statement was filed with the SEC on form S-1 on February 18, 2021, to be completed and filed following the reverse split.
Pursuant to Rule 14c-2 under the Securities Exchange Act of 1934, as amended, the actions described above were not to be implemented until a date at least 20 days after the date on which this Information Statement has been mailed to the stockholders. As a result, the Information Statement became effective on December 10, 2020. As of the date of this Report, the reverse split is pending, subject to approval by the Financial Regulatory Authority (“FINRA”) to which it was submitted for processing on November 20, 2020. Consequently, none of the aforementioned corporate actions have been completed since the reverse split is the first step that needs to be untaken.
As reported on Form 8-K to the SEC on August, 18, 2021, on August 10, 2021, the Company received a letter from the Financial Industry Regulatory Authority (“FINRA”), stating that the Company’s submission to FINRA on November 24, 2020 for the processing and approval of a proposed 1:10 reverse stock split had been denied (the “Stock Split”). FINRA stated the reason that for the denial was in connection with the Company’s deficiency in fulfilling the requirements of FINRA Rule 6480, including, but not limited to, its delinquency to date in the timely filing with the SEC of its 10K for the fiscal year ending December 31, 2020 and its 10Q for the quarter ending March 31, 2021.
As a result of this FINRA letter, the Company’s Board of Directors cancelled the proposed Stock Split, as well as the aforementioned corporate actions connected to it and described in the Information Statement. Since the Rights Offering was hereby cancelled, the Company subsequently withdrew its Registration Statement filed with the SEC on form S-1 on February 18, 2021.
PART III

---

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Item 10. Directors, Executive Officers and Corporate Governance.
Members of our Board of Directors hold office until the next annual general meeting of the stockholders or until their successors are elected and qualified. Our officers are appointed by our Board of Directors and hold office until the earlier of their death, retirement, resignation, removal or expiration of any employment agreement that may exist.
The following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held by each.
Name
Age
Title
Gary Blum
Director, Chairman of the Board of Directors
Lee Lefkowitz
CEO, President/CFO/Director
Gary L. Blum, 80, has been a director and the Chairman of PotNetwork Holdings, Inc. since November 2015 and was its Chief Executive Officer from November 2015 until September 2017. Mr. Blum is also a practicing attorney since 1979 with the Law Offices of Gary L. Blum where his focus is advising a variety of closely held private companies as well as public companies in business, corporate, securities and entertainment law. Mr. Blum has served as a director of Rennova Health, Inc. since October 2017, and, from September 2009 until July 2017, served as the Chairman and CEO of Thunderclap Entertainment, Inc. Mr. Blum received his B.S., Magna Cum Laude, in Mathematics from Loras College in 1962; M.A. in Philosophy from the University of Notre Dame in 1966; and his J.D. and M.B.A. degrees from the University of Southern California Gould School of Law and Marshall School of Business, respectively, in 1978. He has been a member of the California State Bar since 1979.
Lee Lefkowitz, age 50, CEO, President, acting CFO, Director. For much of his career Mr. Lefkowitz has been a serial entrepreneur owning and operating his own businesses. Most recently he has invested in and co-founded All Natural Way Corp. and B2H LLC, companies operating in areas of CBD business that POTN does not. He also was an early investor in several other startup companies. Prior to 2015 he worked as an accountant, focusing on both domestic and international corporate accounts. Mr. Lefkowitz, in addition, has considerable experience managing multi-faceted accounting functions, and in the private sector has overseen and administered an over $10 million annual budget. He holds a BA in Psychology for the State University of New York as well as an AAS in Business Administration.
As reported on Form 8-K on October 27, 2020, Kevin Hagen on October 22, 2020 resigned as Chief Executive Officer, President and a director of PotNetwork Holdings, Inc. Mr. Hagen retains his position as President of First Capital Venture Co., a subsidiary of the Company. Mr. Hagen’s resignation was not the result any disagreement with the Board of Directors of the Company with respect to its operations, policies or practices. He continues to be a significant shareholder of the Registrant.
On November 1, 2020, Murugan Venkat, Chief Financial Officer (“CFO”) of the Company resigned due to other business commitments. As a result, until the Board of Directors of the Company hires a replacement CFO for Mr. Venkat, Mr. Lefkowitz, CEO, on an interim basis has assumed the responsibilities of the CFO position in addition to his position as CEO.
Family Relationships
There are no familial relationships among any of our officers or directors. None of our directors or officers is a director in any other reporting company. The Company is not aware of any proceedings to which any of the Company‚ officers or directors, or any associate of any such officer or director, is a party adverse to the Company or any of the Company subsidiaries or has a material interest adverse to it or any of its subsidiaries.
Corporate Governance
On April 22, 2021, the Company adopted a formal Code of Ethical Conduct. This adoption underscores the Company’s commitment to (i) accountability and the adherence by its employees to honest and ethical behavior; (ii) full, fair, accurate, timely and understandable disclosure in reports and documents filed with the Securities and Exchange Commission as well as any other public communications; and (iii) compliance with all applicable governmental laws, rules and regulations.
The Company’s Board of Directors, is responsible for reviewing and making recommendations concerning the selection of its outside auditors, reviewing the scope, results and effectiveness of the annual audit of the Company’s financial statements, and any and all other services provided by the Company’s third-party contractors and/or accountants. Internal accounting controls, policies and practices are reviewed by the Board of Directors, the Chief Executive Officer and the Chief Financial Officer of the Company.
Committees of the Board
Because of the small size of the Board of Directors, the Company currently does not have nominating, compensation, or audit committees or committees performing similar functions nor does it have a written nominating, compensation or audit committee charter.
Audit Committee Financial Expert
Our Board of Directors has determined that we do not have a board member that qualifies as an “audit committee financial expert” as defined in Item 407(D)(5) of Regulation S-K, nor do we have a Board member that qualifies as “independent” as the term is used in Item 7(d)(3)(iv)(B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(14) of the FINRA Rules.
We believe that our Directors are capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The Directors of our Company do not believe that it is necessary to have an audit committee because management believes that the Board of Directors can adequately perform the functions of an audit committee.
Involvement in Certain Legal Proceedings
Except as disclosed below, our Directors and our Executive officers have not been involved in any of the following events during the past ten years:
1.
bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
2.
any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
3.
being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his/her involvement in any type of business, securities or banking activities; or
4.
being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.
5.
Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;
6.
Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;
7.
Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment ,decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:(i) Any Federal or State securities or commodities law or regulation; or(ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or(iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
8.
Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.
As reported on Form 8-K on April 29, 2021, the United States Attorney for the Northern District of Ohio file an indictment that included charges against Kevin Hagen, the former CEO of the Registrant and the president of First Capital Venture Company. (The Company has not been charged with any wrongdoing and has not been contacted by any law enforcement agency regarding these charges and allegations.) The case remains ongoing.
Independence of Directors
We are not required to have independent members of our Board of Directors, and do not anticipate having independent Directors until such time as we are required to do so.
Code of Ethics
On April 22, 2021, the Company adopted a formal Code of Ethical Conduct. Prior to this date, the Company had not adopted one. This adoption underscores the Company’s commitment to (i) accountability and the adherence by its employees to honest and ethical behavior; (ii) full, fair, accurate, timely and understandable disclosure in reports and documents filed with the Securities and Exchange Commission as well as any other public communications; and (iii) compliance with all applicable governmental laws, rules and regulations.
Shareholder Proposals
Our Company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors. The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such nominees. The Board of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.
A shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our President, at the address appearing on the first page of this report.

---

ITEM 11. EXECUTIVE COMPENSATION
Item 11. Executive Compensation.
The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our chief executive officer for services rendered in all capacities for the periods set forth below.
Summary Compensation Table
Nonqualified
Non-Equity
Deferred
Name and
Stock
Option
Incentive Plan
Compensation
All Other
Principal
Bonus
Awards
Awards
Compensation
Earnings
Compensation
Total
Position
Year
Salary
($)
($)
($)
($)
($)
($)
($)
Lee Lefkowitz, CEO (1)
52,000
52,000
Kevin Hagen
135,000
110,000
Former CEO (2)
130,000
130,000
10,000
10,000
Richard Goulding
49,000
49,000
Former CEO (3)
16,000
16,000
Gary Blum
Director
170,000
170,000
(1)
Stated as annual salary for a 12-month period. During 2020 he earned apportionment from Oct 22, 2020 to December 31, 2020, in the amount of $7,400.
(2)
Kevin Hagen resigned as CEO on October 22, 2020 and was replaced by Lee Lefkowitz, as President and CEO.
(3)
Richard Goulding, M.D., resigned as CEO on October 25, 2018 and was replaced by Kevin Hagen, Esq. as CEO.
(4)
Represents accrued salary attributed to that period in the employment agreement with Dr. Goulding entered into in July 2018.
Employment Agreements
The Company entered into an employment agreement with Richard Goulding, M.D., prior CEO, on July 9, 2018 retroactive to September 5, 2017, for a period of one year. He was not engaged by the Company prior to that date. Under the terms of the agreement, Dr. Goulding received a base salary, received a initial common stock grant and common stock options. The agreement has expired and was not renewed.
The Company entered into an employment agreement with Lee Lefkowitz, President and CEO, on October 23, 2020 for a period of 24 months. He was not engaged by the Company prior to that date. Under the terms of the agreement, Mr. Lefkowitz receives a base salary and is to receive a common stock grant of 1,000,000 shares of restricted common stock during 2021.
The Company does not have, and has not had, any employment agreements with any other officers and directors.
Compensation of Directors
Gary Blum, Director and Chairman of the Board, was issued 2,000,000 shares of restricted common stock in 2019 in recognition of services performed in prior years as a director of the Company. Lee Lefkowitz receives no compensation for being a member of the Board of Directors of the Company. Mr. Blum and Mr. Lefkowitz are the only directors of the Company. As of the date of this Report, the Board of Directors does not have a written policy on director compensation.

---

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
As of September 27, 2021, we had 909,974,924 common shares outstanding. The following table sets forth certain information regarding our shares of common stock beneficially owned as of this date, for (i) each stockholder known to be the beneficial owner of five percent (5%) or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial ownership at any time within sixty (60) days through an exercise of stock options or warrants or otherwise. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.
For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within sixty (60) days of the date of this Report. Ownership is determined in accordance with Section 13(d) of the Securities Exchange Act of 1934. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within sixty (60) days of the date of this Report is deemed to be outstanding but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership.
AMOUNT AND NATURE OF BENEFICIAL OWNERSHIP
Common Stock
Name and Address of Beneficial Owner (2)
Direct
Indirect
Total
Percentage
of Class (1)
Executive Officers and Directors
Gary Blum
2,000,000
2,000,000
.22 %
Lee Lefkowitz (3)
1,000,000
1,000,000
.11 %
Officers and Directors as a Group
Other 5% Holders (4)
Elinor Taieb
64,651,438
64,651,438
7.10 %
Class A Preferred Stock (5)
Direct
Indirect
Total
Percentage
of Class
Kevin Hagen
20,742
20,742
60.4 %
Elinor Taieb
13,547
13,597
39.5 %
____________
(1)
Based on a total of issued and outstanding shares as of September 27, 2021 of 909,974,924.
(2)
(3)
The address of each officer is 3531 Griffin Road, Fort Lauderdale, Florida 33312.
Lee Lefkowitz is to be issued 1,000,000 shares of restricted common stock per his employment agreement. Issuance is pending within 60 days of the date of this Report.
(4)
Pursuant to the Convertible Promissory Notes (“Notes”) that the Company has with Sign N Drive Auto Mall, Inc., and Iliad Research and Trading, LP, (“Iliad”), the Company is prohibited from issuing shares to either of these noteholders if such issuance would cause either noteholder individually to own more than 4.99% of the number of common shares of the Company outstanding at the time of such issuance. Thus, while said noteholders may convert their Notes over time into more than 4.99% of the then issued and outstanding shares of common stock of the Company, neither of them may own more than 4.99% of the common shares of the Company at any one time and therefore neither is included in the above table of beneficial ownership. Moreover, as of the date of this Report, either of the aforementioned noteholders hold any shares of any class of stock in the Company.
(5)
Each share of Class A preferred stock is convertible into 0.01% of the total number of shares of Common Stock outstanding at the Conversion Time. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
Based on the preceding and upon a total quantity of issued and outstanding shares as of September 27, 2021 of 909,974,924, each share of Class A preferred stock is convertible into 90,997 shares of common stock. As a result, if each of the two Class A preferred shareholders listed were able to convert 100% of each’s Class A preferred stock, Kevin Hagen, who holds 20,742 Class A preferred shares, would receive 1,887,459,774 shares of common stock; and Elinor Taieb, who holds 13,547 Class A preferred shares, would receive 1,232,736,359 shares of common stock.
In addition to Class A preferred stock, Kevin Hagen holds 27,750,000 shares of restricted common stock of the Company, equivalent to 3.05% of the total quantity of common shares issued and outstanding as of September 27, 2021 of 909,974,924. Also, during fiscal 2019, Distribution Wholesale, Inc., a Florida corporation, of which Kevin Hagen, is a principal, advanced to the Company $1,626,588.64 (the “Advances”) in the form of payments to several suppliers. The Board of Directors of the Company, in settlement of the debt created by the Advances, issued to Distribution Wholesale, Inc. a Common Stock Purchase Warrant, exercisable over 5 years, for 75,305,030 shares of common stock of the Company at a price per share of $.0216, the closing market price of December 31, 2019 as reported by OTC Markets.
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT
Section 16(a) of the Exchange Act requires officers, directors and persons who own more than 10% of a registered class of our equity securities of a Company that has a class of common stock registered under the Exchange Act to file reports of ownership and changes in ownership with the Securities and Exchange Commission and to furnish us with copies of all forms filed pursuant to Section 16(a).
Based solely on a review of the copies of such reports furnished to us, we believe that our officers and directors and our principal stockholder who are required to file reports pursuant to Section 16(a) of the Exchange Act complied with all of the Section 16(a) filing requirements applicable to them with respect to the last fiscal year.

---

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, DIRECTOR INDEPENDENCE
Related Party Transactions
PotNetwork Holding, Inc. maintains its offices at 3531 Griffin Road, Fort Lauderdale, FL 33312. The space is provided to it at no cost by Kevin Hagen, Esq., a principal shareholder of the Company and President of our wholly owned subsidiary, First Capital Venture Co.
During fiscal 2019, Distribution Wholesale, Inc., a Florida corporation, of which Kevin Hagen, is a principal, advanced to the Company $1,626,588.64 (the “Advances”) in the form of payments to several suppliers. On December 31, 2019, the Board of Directors of the Company, in settlement of the debt created by the Advances, issued to Distribution Wholesale, Inc. a Common Stock Purchase Warrant, exercisable over 5 years, for 75,305,030 shares of common stock of the Company at a price per share of $.0216, the closing market price of December 31, 2019 as reported by OTC Markets. Consequently, the Advances have been recorded as additional Paid-In Capital on the Balance Sheet of the Company for the year-ended December 31, 2019.

---

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
Item 14. Principal Accountant Fees and Services.
During 2020 and 2019, the Company’s independent auditors have billed for their services as set forth below. In addition, fees and services related to the audit of the financial statements of the Company for the period ended December 31, 2020, as contained in this Report, are estimated and included for the fiscal year ended December 31, 2019.
Year ended December 31,
Audit Fees
$ 43,070
$ 30,000
Audit-Related Fees
$ -0-
$ -0-
Tax Fees
$ -0-
$ -0-
All Other Fees
$ -0-
$ -0-
PART IV

---

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) Financial Statements
The following are filed as part of this report:
Financial Statements
The following financial statements of PotNetwork Holdings Inc. and Report of Independent Registered Public Accounting Firm are presented in the “F” pages of this Report:
(b) Exhibits
Exhibit No.
Description
2.1
Share Exchange Agreement with First Capital Venture Co.*
3.1
Articles of Incorporation*
3.1-1
Amendment to Articles of Inc., February 5, 2020 (1)
3.2
Bylaws*
10.1
Purchase Agreement with PotNetwork Media Group, Inc.*
10.2
Employment Agreement with Richard Goulding*
10.3
Securities Purchase Agreement Dated October 25, 2018*
10.4
Convertible Note Dated October 25, 2018*
10.5
Securities Purchase Agreement Dated February 7, 2019*
10.6
Convertible Note Dated February 7, 2019*
10.7
Common Stock Purchase Warrant dated December 31, 2019**
10.8
SBA PPP Loan May 6, 2020***
10.9
SBA Economic Injury Disaster Loan June 18, 2020***
10.10
SBA PPP Loan March 10, 2021***
10,11
Resignation of Kevin Hagen, October 22, 2020***
10.12
Information Statement, November 20, 2020***
10,13
BOD Resolution Accepting Hagen Resignation and Lee Lefkowitz Appointment, October 22, 2020***
10,14
Lee Lefkowitz Employment Agreement***
10.15
Code of Ethical Conduct***
23.1
Consent of Yusufali & Associates***
31.1
Certification of Principal Executive Officer as required by Rule 13a-14 or 15d-14 of the Exchange Act, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002***
31.2
Certification of Principal Accounting Officer as required by Rule 13a-14 or 15d-14 of the Exchange Act, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002***
32.1
Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***
32.2
Certification of Principal Accounting Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***
_________
*Previously filed on the Company’s Registration Statement on Form 10 on May 9, 2019
**Previously filed as Exhibit 10.7 on Form 10-K on July 23, 2020.
(1) Filed as Exhibit 3.1 on Form 8-K dated February 6, 2020
***Filed herewith